# Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer

> **NCT00898794** · — · UNKNOWN · sponsor: **Kantonsspital Graubuenden** · enrollment: 20 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** bevacizumab
- **OTHER:** coagulation study
- **OTHER:** laboratory biomarker analysis
- **OTHER:** platelet aggregation test

## Key facts

- **NCT ID:** NCT00898794
- **Lead sponsor:** Kantonsspital Graubuenden
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2009-05
- **Final completion:** —
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2013-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00898794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00898794, "Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00898794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*